does blue cross blue shield cover glp-1 drugs Alternatives to medication? Blue Cross Blue Shield of

Who Should Not Take GLP-1 Agonists

Nutrition , 27(3), 327333

Overall, our findings remained consistent across multiple sensitivity analyses

Fat produces estrogen, which promotes certain breast cancer subtypes

This prolonged, supraphysiological stimulation results in greater glucose-lowering effects, more pronounced appetite suppression, and clinically significant weight loss that varies by medication and dose: approximately 5-8% with liraglutide 3 mg, 10-15% with semaglutide 2.4 mg, and 15-22% with tirzepatide at higher doses

However, weight loss induced by GLP-1RAs encompasses both fat and lean tissue compartments and could be associated to nutritional deficiencies, raising important questions regarding their impact on skeletal muscle, particularly in individuals at increased risk of sarcopenia [11]